Elevated Intraoperative Expression of Ventricular Myosin Light Chain Predicts Heart Failure after Valve Replacement Surgery
Background: It can be difficult to predict which patients will survive and recover cardiac function after valve replacement surgery. We hypothesized that the expression levels of ventricular myosin light chain (MLCv) might reflect the severity of disease or the extent of irreversible myocardial damage and might be useful for predicting the postoperative course. Thus, the aim of this study was to explore the relationship between MLCv expression in specimens obtained during valve replacement surgery and the postoperative New York Heart Association (NYHA) class.
Methods: The levels of expression of the regulatory MLCv (MLC-2v) and MLC-1v in papillary muscle specimens from 80 patients who underwent valve replacement surgery for rheumatic valvular disease were evaluated by Western blot analysis.
Results: The patients were similar with regard to the intraoperative expression of MLC-1v, regardless of postoperative NYHA class. The preoperative NYHA class, the end-systolic left ventricular internal dimension, and the intraoperative expression of MLC-2v emerged as independent risks factors for a NYHA class status of III/IV at 6 months after surgery, with an area under the receiver operating characteristic curve of 0.862.
Conclusion: The intraoperative level of MLC-2v expression was predictive of the patients' NYHA class after valve replacement surgery. This result suggests that future studies evaluating the use of preoperative specimens (such as biopsy or peripheral blood samples) for measurement of MLC-2v levels could lead to a valuable preoperative tool for the assessment of candidates for valve replacement.
Bergler-Klein J. 2009. Natriuretic peptides in the management of aortic stenosis. Curr Cardiol Rep 11:85-93.nChen J, Kubalak SW, Minamisawa S, et al. 1998. Selective requirement of myosin light chain 2v in embryonic heart function. J Biol Chem 273:1252-6.nCunningham MW. 2000. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 13:470-511.nDavis JS, Hassanzadeh S, Winitsky S, et al. 2001. The overall pattern of cardiac contraction depends on a spatial gradient of myosin regulatory light chain phosphorylation. Cell 107:631-41.nDavis JS, Satorius CL, Epstein ND. 2002. Kinetic effects of myosin regulatory light chain phosphorylation on skeletal muscle contraction. Biophys J 83:359-70.nDella Corte A, Salerno G, Chiosi E, et al. 2008. Preoperative, postoperative and 1-year follow-up N-terminal pro-B-type natriuretic peptide levels in severe chronic aortic regurgitation: correlations with echocardiographic findings. Interact Cardiovasc Thorac Surg 7:419-24.nDias FA, Walker LA, Arteaga GM, et al. 2006. The effect of myosin regulatory light chain phosphorylation on the frequency-dependent regulation of cardiac function. J Mol Cell Cardiol 41:330-9.nFlores-Marín A, Gómez-Doblas JJ, Caballero-Borrego J, et al. 2010. Long-term predictors of mortality and functional recovery after aortic valve replacement for severe aortic stenosis with left ventricular dysfunction. Rev Esp Cardiol 63:36-45.nFrustaci A, Magnavita N, Chimenti C, Caldarulo M, Sabbioni E, Pietra R. 1999. Marked elevation of myocardial trace elements in idiopathic dilated cardiomyopathy compared with secondary cardiac dysfunction. J Am Coll Cardiol 33:1578-83.nGoto T, Takase H, Toriyama T, et al. 2003. Circulating concentrations of cardiac proteins indicate the severity of congestive heart failure. Heart 89:1303-7.nGreenberg MJ, Kazmierczak K, Szczesna-Cordary D, Moore JR. 2010. Cardiomyopathy-linked myosin regulatory light chain mutations disrupt myosin strain-dependent biochemistry. Proc Natl Acad Sci U S A 107:17403-8.nGuilherme L, Kalil J. 2010. Rheumatic fever and rheumatic heart disease: cellular mechanisms leading to autoimmune reactivity and disease. J Clin Immunol 30:17-23.nHernandez OM, Jones M, Guzman G, Szczesna-Cordary D. 2007. Myosin essential light chain in health and disease. Am J Physiol Heart Circ Physiol 292:H1643-54.nHoffmann PA, Metzger JM, Greaser ML, Moss RL. 1990. The effects of partial extraction of light chain 2 on Ca2+ sensitivities of isometric tension stiffness and velocity of shortening in skinned skeletal muscle fibers. J Gen Physiol 95:477-98.nJacques AM, Briceno N, Messer AE, et al. 2008. The molecular pheno-type of human cardiac myosin associated with hypertrophic obstructive cardiomyopathy. Cardiovasc Res 79:481-91.nKockskämper J, von Lewinski D, Khafaga M, et al. 2008. The slow force response to stretch in atrial and ventricular myocardium from human heart: functional relevance and subcellular mechanisms. Prog Biophys Mol Biol 97:250-67.nLee W, Hwang TH, Kimura A, et al. 2001. Different expressivity of a ventricular essential myosin light chain gene Ala57Gly mutation in familial hypertrophic cardiomyopathy. Am Heart J 141:184-9.nMargossian SS, White HD, Caulfield JB, Norton P, Taylor S, Slayter HS. 1992. Light chain 2 profile and activity of human ventricular myosin during dilated cardiomyopathy. Identification of a causal agent for impaired myocardial function. Circulation 85:1720-33.nMorano M, Zacharzowski U, Maier M, Lange PE, Alexi-Meskishvili V, Haase H. 1996. Regulation of human heart contractility by essential myosin light chain isoforms. J Clin Invest 98:467-73.nNussinovitch U, Shoenfeld Y. 2011. The clinical and diagnostic significance of anti-myosin autoantibodies in cardiac disease. Clin Rev Allergy Immunol. In press.nOlsson MC, Patel JR, Figzsimons DP, Walker JW, Moss RL. 2004. Basal myosin light chain phosphorylation is a determinant of Ca2+ sensitivity of force and activation dependence of the kinetics of myocardial force development. Am J Physiol Heart Circ Physiol 287:H2712-8.nRottbauer W, Wessels G, Dahme T, et al. 2006. Cardiac myosin light chain-2: a novel essential component of thick-myofilament assembly and contractility of the heart. Circ Res 99:323-31.nSato Y, Kita T, Takatsu Y, Kimura T. 2004. Biochemical markers of myocyte injury in heart failure. Heart 90:1110-3.nSeguchi O, Takashima S, Yamazaki S, et al. 2007. A cardiac myosin light chain kinase regulates sarcomere assembly in the vertebrate heart. J Clin Invest 117:2812-24.nSolaro RJ. 1992. Myosin and why hearts fail. Circulation 85:1945-7.nSütsch G, Brunner UT, von Schulthess C, et al. 1992. Hemodynamic performance and myosin light chain-1 expression of the hypertrophied left ventricle in aortic valve disease before and after valve replacement. Circ Res 70:1035-43.nTarantini G, Buja P, Scognamiglio R, et al. 2003. Aortic valve replacement in severe aortic stenosis with left ventricular dysfunction: determinants of cardiac mortality and ventricular function recovery. Eur J Cardiothorac Surg 24:879-85.nTrahair T, Yeoh T, Cartmill T, et al. 1993. Myosin light chain gene expression associated with disease states of the human heart. J Mol Cell Cardiol 25:577-85.nVaquette B, Corbineau H, Laurent M, et al. 2005. Valve replacement in patients with critical aortic stenosis and depressed left ventricular function: predictors of operative risk, left ventricular function recovery, and long term outcome. Heart 91:1324-9.nVillar AV, Llano M, Cobo M, et al. 2009. Gender differences of echocardiographic and gene expression patterns in human pressure overload left ventricular hypertrophy. J Mol Cell Cardiol 46:526-35.nWeber M, Hausen M, Arnold R, Nef H, Moellman H, Berkowitsch A. 2006. Prognostic value of N-terminal pro-B-type natriuretic peptide for conservatively and surgically treated patients with aortic valve stenosis. Heart 92:1639-44.n
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).